1-3 of 3
Ying Fei Li
Close
Sort by
Journal Articles

Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation

Francois Pierre Combes, Ying Fei Li, Sherwin K.B. Sy, Sebastien Lorenzo, Kohinoor Dasgupta, Shruti Kapoor, Matthias Hoch, Yu-Yun Ho
Journal: Blood
Blood (2022) 140 (Supplement 1): 6791–6792.
https://doi.org/10.1182/blood-2022-163078
Published: 2022
Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4089.
https://doi.org/10.1182/blood-2019-125310
Published: 2019
Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1320.
https://doi.org/10.1182/blood-2019-125363
Published: 2019